J
Joan H. Schiller
Researcher at University of Wisconsin-Madison
Publications - 160
Citations - 29240
Joan H. Schiller is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 156 publications receiving 27937 citations. Previous affiliations of Joan H. Schiller include University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Novel agents in the treatment of lung cancer: conference summary statement.
Thomas J. Lynch,Alex A. Adjei,Paul A. Bunn,Raymond N. DuBois,David R. Gandara,Giuseppe Giaccone,Ramaswamy Govindan,Roy S. Herbst,Bruce E. Johnson,Fadlo R. Khuri,Roman Perez-Soler,Rafael Rosell,Eric K. Rowinsky,Alan B. Sandler,Giorgio V. Scagliotti,Joan H. Schiller,Geoffrey I. Shapiro,Mark A. Socinski,Carol S. Hart +18 more
TL;DR: A small, international, closed-door conference on Novel Agents in the Treatment of Lung Cancer, held in Cambridge, Massachusetts, October 17–18, 2003, was convened to present and discuss findings from recent and ongoing trials of investigational drugs for the treatment of lung cancer.
Journal ArticleDOI
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Joan H. Schiller,Barry E. Storer,Donna M. Paulnock,Raymond R. Brown,Surinder P. Datta,Patricia L. Witt,Ernest C. Borden +6 more
TL;DR: Induction of induced proteins (with exception of influences on tryptophan catabolism) were not a function of dose administered over the 10-fold range, and these IFNs did not result in potentiation of biological response modification in vivo.
Journal ArticleDOI
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
TL;DR: This article focuses on tyrosine kinase inhibitors of the VEGF receptors and presents phase I data (and phase II/III data when available) of these compounds and discusses their potential development in the treatment of lung cancer.
Journal ArticleDOI
Phase II Trial of a Combination of Interferon-βser and Interferon-γ in Patients with Advanced Malignant Melanoma
TL;DR: A Phase II trial using the interferon-β and IFN-γ combination to determine the clinic success rate in patients with advanced melanoma is initiated.
Journal ArticleDOI
Systemic treatment of advanced non-small cell lung cancer.
Anne M. Traynor,Joan H. Schiller +1 more
TL;DR: The focus of clinical research is centered on the application of the use of targeted, molecularly directed therapies, likely used in combination with either cytotoxics and/or other novel targeted agents, in an attempt to improve the therapeutic ratio of systemic treatments for this large population.